FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 282 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer Aiming to support a robust regulatory ecosystem for driving cancer research in Europe, ESMO provides feedback to the public consultation on dataset descriptions under... MOST POPULAR New on NCI’s Websites for August 2024 August 16, 2024 Advances in Treating Kidney Cancer and Metastatic Prostate Cancer: Research from... January 25, 2024 FDA Approves Daratumumab and Hyaluronidase-fihj with Bortezomib, Lenalidomide, and Dexamethasone for... September 12, 2024 Why the Bone Marrow Registry Needs More Diverse Donors and How... March 30, 2021 Load more HOT NEWS Can Topical Drugs Help Prevent Breast Cancer? BREAKING: President Trump May Restore The WHO’s Funding, With Some Conditions Judge Rules That 3-Year-Old Child With Leukemia Must Get Chemo Against... Comme louer son affaire en compagnie de tacht mahometane? (2023)
